Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key ...
While autologous therapies are mainstream in blood cancers, experts warn against overhyping allogeneic and in vivo approaches ...
The advent of chimeric antigen receptor (CAR)-T cell therapy has marked the onset of a very promising option to treat solid tumors after its remarkable ...
An in vivo chimeric antigen receptor T-cell therapy administered without lymphodepletion exhibited activity among patients with advanced multiple myeloma, according to findings presented at ASH Annual ...
The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...
ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...
Potent CAR-T expansion from a single, off-the-shelf infusion without chemotherapy ...
Outpatient CAR T-cell therapy shows promising efficacy and manageable safety in treating relapsed multiple myeloma, with high response rates and minimal long-term toxicity.
A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...
Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene ...
Lisocabtagene maraleucel (liso-cel) is now the only CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for MZL. The approval marks liso-cel’s fifth indication, the most of any ...
The CAR T-cell therapy market offers significant growth opportunities driven by technological advancements, personalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results